A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

• Status: Terminated
• Trial end date: 1969-12-31

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD), safety and toxicity when cyclophosphamide, rituximab and lenalidomide (Revlimid) are combined for the treatment of relapsed/refractory of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

• Phase: Phase 1

Details

• Lead Sponsor: Emory University
• Collaborator: Celgene Corporation
• Treatments: Cyclophosphamide; Lenalidomide; Rituximab